These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 38688611)
1. Targeting Methionine Addiction Combined With Low-dose Irinotecan Arrested Colon Cancer in Contrast to High-dose Irinotecan Alone, Which Was Ineffective, in a Nude-mouse Model. Sato M; Mizuta K; Han Q; Morinaga S; Kang BM; Kubota Y; Mori R; Baranov A; Kobayashi K; Ardjmand D; Kobayashi N; Bouvet M; Ichikawa Y; Nakajima A; Hoffman RM In Vivo; 2024; 38(3):1058-1063. PubMed ID: 38688611 [TBL] [Abstract][Full Text] [Related]
2. Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon Cancer. Sato M; Han Q; Kubota Y; Baranov A; Ardjmand D; Mizuta K; Morinaga S; Kang BM; Kobayashi N; Bouvet M; Ichikawa Y; Nakajima A; Hoffman RM Anticancer Res; 2024 Jan; 44(1):31-35. PubMed ID: 38159986 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Tan Y; Sun X; Xu M; Tan X; Sasson A; Rashidi B; Han Q; Tan X; Wang X; An Z; Sun FX; Hoffman RM Clin Cancer Res; 1999 Aug; 5(8):2157-63. PubMed ID: 10473100 [TBL] [Abstract][Full Text] [Related]
4. Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis. Kim MJ; Han Q; Bouvet M; Hoffman RM; Park JH Anticancer Res; 2023 Jan; 43(1):19-24. PubMed ID: 36585181 [TBL] [Abstract][Full Text] [Related]
5. Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet. Sato M; Han Q; Mori R; Mizuta K; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM Anticancer Res; 2024 Apr; 44(4):1499-1504. PubMed ID: 38538002 [TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models. Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105 [TBL] [Abstract][Full Text] [Related]
7. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer. Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758 [TBL] [Abstract][Full Text] [Related]
8. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model. Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871 [TBL] [Abstract][Full Text] [Related]
9. First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulted in 40% Tumor Reduction and an 86% CA19-9 Biomarker Decrease. Sato M; Han Q; Hozumi C; Kujiraoka H; Mizuta K; Morinaga S; Kang BM; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM Anticancer Res; 2024 Sep; 44(9):3885-3889. PubMed ID: 39197890 [TBL] [Abstract][Full Text] [Related]
10. Selective Synergy of Rapamycin Combined With Methioninase on Cancer Cells Compared to Normal Cells. Ardjmand D; Kubota Y; Sato M; Han Q; Mizuta K; Morinaga S; Hoffman RM Anticancer Res; 2024 Mar; 44(3):929-933. PubMed ID: 38423628 [TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan. Riviere K; Kieler-Ferguson HM; Jerger K; Szoka FC J Control Release; 2011 Aug; 153(3):288-96. PubMed ID: 21600250 [TBL] [Abstract][Full Text] [Related]
12. Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Murakami T; Li S; Han Q; Tan Y; Kiyuna T; Igarashi K; Kawaguchi K; Hwang HK; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Hiroshima Y; Lwin TM; DeLong JC; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM Oncotarget; 2017 May; 8(22):35630-35638. PubMed ID: 28404944 [TBL] [Abstract][Full Text] [Related]
13. Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse Model. Masaki N; Han Q; Samonte C; Wu NF; Hozumi C; Wu J; Obara K; Kubota Y; Aoki Y; Bouvet M; Hoffman RM Anticancer Res; 2022 Nov; 42(11):5217-5222. PubMed ID: 36288875 [TBL] [Abstract][Full Text] [Related]
14. Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Sugisawa N; Higuchi T; Han Q; Hozumi C; Yamamoto J; Tashiro Y; Nishino H; Kawaguchi K; Bouvet M; Murata T; Unno M; Hoffman RM Cancer Chemother Pharmacol; 2021 Jul; 88(1):61-67. PubMed ID: 33768300 [TBL] [Abstract][Full Text] [Related]
15. A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model. Kiyuna T; Tome Y; Murakami T; Miyake K; Igarashi K; Kawaguchi K; Oshiro H; Higuchi T; Miyake M; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Chawla S; Kanaya F; Eilber FC; Singh SR; Zhao M; Hoffman RM Biochem Biophys Res Commun; 2018 Nov; 505(3):733-739. PubMed ID: 30292411 [TBL] [Abstract][Full Text] [Related]
16. Oral Installation of Recombinant Methioninase-producing Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Baranov A; Bouvet M; Tsunoda T; Hoffman RM Cancer Genomics Proteomics; 2022; 19(6):683-691. PubMed ID: 36316039 [TBL] [Abstract][Full Text] [Related]
17. Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease. Kubota Y; Han Q; Hozumi C; Masaki N; Yamamoto J; Aoki Y; Tsunoda T; Hoffman RM Anticancer Res; 2022 May; 42(5):2567-2572. PubMed ID: 35489727 [TBL] [Abstract][Full Text] [Related]
18. Green tea catechins in combination with irinotecan attenuates tumorigenesis and treatment-associated toxicity in an inflammation-associated colon cancer mice model. Borah G; Bharali MK J Egypt Natl Canc Inst; 2021 Jul; 33(1):17. PubMed ID: 34308509 [TBL] [Abstract][Full Text] [Related]
19. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Pencreach E; Guérin E; Nicolet C; Lelong-Rebel I; Voegeli AC; Oudet P; Larsen AK; Gaub MP; Guenot D Clin Cancer Res; 2009 Feb; 15(4):1297-307. PubMed ID: 19190131 [TBL] [Abstract][Full Text] [Related]
20. Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model. Park JH; Han Q; Zhao M; Tan Y; Higuchi T; Yoon SN; Sugisawa N; Yamamoto J; Bouvet M; Clary B; Singh SR; Hoffman RM Tissue Cell; 2019 Dec; 61():109-114. PubMed ID: 31759402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]